The 2023 LOI process for all Curebound Grants is now open. For more information on how to apply, please click here.

Donate
Curebound
[object Object],[object Object]

THE POWER OF
COLLABORATION

The best ideas happen when the right people work together.

Curebound
Curebound

TARGETED
INVESTMENTS

INVESTMENT PILLARS & AREAS OF OPPORTUNITY

Collaboration is at the center of Curebound’s unique grantmaking platform. All Curebound grants demand collaboration among specialized teams from our research partner institutions, enabling the brightest minds from different scientific disciplines to work together to produce better options and outcomes for patients. Curebound research partners include:

  • Moores Cancer Center at UC San Diego Health
  • Salk Institute
  • Sanford-Burnham Prebys
  • Rady Children’s Hospital
  • La Jolla Institute for Immunology
  • Scripps Research

Curebound funds promising, innovative oncology research for all types of cancer, adult and pediatric, in alignment with five scientific investment pillars:

  • Prevention and diagnostic tools
  • Novel approaches and new therapeutic platforms
  • Immunotherapies and personalized vaccines
  • Cancer equities
  • Pediatric cancers

CUREBOUND GRANTS

Curebound funds three levels of cancer research grants. For information on our annual grant cycle and application process, please contact our Grants Department via rahul@curebound.org

Discovery Grants

One-time seed grants of up to $250,000 for high-risk/high-reward, translational research. Ideas are innovative and in the early phases where smaller grants can make a big impact in advancing research.

Curebound

Targeted Grants

Larger gifts of $500,000 that aim to fund projects that are closer to clinical stages. Targeted Grants require a clinical researcher to be part of the collaborative team in order to ensure the project is geared toward translational application.

Curebound

Cure Prizes

Innovative, multi-disciplinary projects that receive major funding of $1,000,000+ to be administered over multiple years. The first Cure Prize challenge is to develop an innovation that will improve the standard of care for a typically deadly cancer with patient application in 3-5 years.

Curebound

RESEARCH PORTFOLIO

Curebound raises and invests strategic funding in translational cancer research projects aimed at accelerating new discoveries to clinical application. The full index of our research portfolio is available below.

FILTER BY

Cancer Type

Institution

Pillar

Year

Decoding the Role of the Long Non-Coding RNA PVT1 in Medulloblastoma

2022: Brain

Medulloblastoma is the most common malignant childhood brain tumor. It is a highly heterogeneous cancer, comprising four subgroups: Sonic Hedgehog, Wingless, Group 3, and Group 4. Group 3 MB has the worst prognosis of all Medulloblastomas. Group 3 often exhibits amplification of chromosome 8q24, which contains the potent oncogene MYC.

Read More

Determining the Impact of Regulatory Mutations and Dysregulated Transcription Factors in Neuroblastoma

2022: Brain

Neuroblastoma is a tumor of developmental origin with high incidence of metastatic disease at initial diagnosis. Comprehensive DNA sequencing of high-risk neuroblastoma has identified few clinically actionable gene mutations and precision medicine has not benefited most neuroblastoma patients.

Read More

Therapeutics to Overcome the Differentiation Roadblock in Myelodysplastic Syndrome (MDS)

2022: Leukemia

Myelodysplastic syndrome (MDS) is a pre-cancer condition involving mutations in the stem cells which give rise to the many cell types which compose blood. These mutations cause stem cells to produce red blood cells and other cell types less efficiently, conditions called cytopenias — complications to which most MDS patients succumb.

Read More

Neoantigen Driven Eradication of Immune-Reprogrammed Ovarian Cancer

2022: Ovarian

One approach to treating tumors uses intravenous therapies that help the immune system. This works in many cancers, however, this approach does not always work, and can fail with time as tumors find ways to avoid the immune system – even shutting off its ability to attack tumors.

Read More

Targeting Metabolic Vulnerabilities Unique to Pancreatic Ductal Adenocarcinoma

2022: Pancreatic

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a 5-year survival rate of 11%. Most patients die within 6 months of diagnosis from metastatic disease, but even patients who qualify for surgical resection eventually succumb to the disease. No targeted therapies are available.

Read More

High Throughput-Screen for Inhibitors of Pediatric Ependymoma

2022: Pediatric

Brain and other tumors of the central-nervous system (CNS) are the most common cancers in children aged 0- 14 years in the USA. Ependymoma (EPN) is the third most common pediatric brain tumor and a leading cause of death in childhood cancer patients.

Read More

Targeting Tumor-Associated Macrophages to Improve Immunotherapy in Neuroblastoma

2022: Brain

Neuroblastoma is a cancer that accounts for more than 15% of all childhood cancer deaths. Despite multimodal therapy, the 5-year survival rate of children with high-risk disease is very low. Hence, novel, and safe therapies are needed to combat this childhood cancer. Here, we propose a targeted strategy to improve the effectiveness of anti-cancer therapy for this childhood cancer.

Read More

HERV env: A Targetable Surface Protein in Ovarian Cancer

2022: Ovarian

Hundreds of thousands of years ago, before humans evolved from primates, another pandemic caused by viruses occurred. This pandemic was caused by retroviruses, which are viruses that can insert their own genetic information into the DNA of their hosts.

Read More

Pre-Clinical Development of New Autophagy Targeting Drugs for Bone Metastatic Prostate Cancer

2022: Prostate

One in six men will be diagnosed with prostate cancer (PCa), making it one of the leading health problems affecting men in today’s society. Patients diagnosed during the earlier stages are surviving longer due to improved therapies and the prevalence of prostate-specific antigen (PSA) testing.

Read More
Curebound

INSTITUTIONAL RESEARCH
PARTNERS

Curebound funds innovative, collaborative research between these six cancer research centers in San Diego.

undefined undefined
undefined undefined
undefined undefined
undefined undefined
undefined undefined
undefined undefined

RESOURCES

Curebound 2022 Annual Report undefined

Curebound 2022 Annual Report

Curebound 2022 Video undefined

Curebound 2022 Video

Curebound

EXPLORATION

Curebound
Curebound

ACCELERATION

Curebound
Curebound

COLLABORATION

Curebound
Curebound

CURES

Curebound 2022 Concert Featuring Alicia Keyes
Curebound 2022 Concert Featuring Alicia Keyes

HOW WOULD YOU LIKE TO REGISTER?

To join a team that participated in a previous Padres Pedal the Cause event or that has already been created for 2023, click ‘JOIN A TEAM’, and enter your team’s name.

AS AN
INDIVIDUAL

JOIN A
TEAM

CREATE A
TEAM